ACAD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

293.24M

+12.96%

0.142

-83.54%

283.10M

+15.88%

0.115

+4.55%

304.72M

+15.18%

0.188

+17.19%

Estimates Revision

The market is revising Upward the revenue expectations for ACADIA Pharmaceuticals Inc. (ACAD) for FY2025, with the revenue forecasts being adjusted by 0.95% over the past three months. During the same period, the stock price has changed by 33.50%.

Revenue Estimates for FY2025

Revise Upward

+0.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+45.2%

In Past 3 Month

Stock Price

Go Up

+33.50%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

21.00

Averages

30.24

High

39.00

Current: 0.000

Low

21.00

Averages

30.24

High

39.00

UBS

Ashwani Verma

Buy

maintain

$35 -> $40

2026-01-06

New

Reason

UBS

Ashwani Verma

Price Target

$35 -> $40

2026-01-06

New

maintain

Buy

Reason

UBS analyst Ashwani Verma raised the firm's price target on Acadia Pharmaceuticals to $40 from $35 and keeps a Buy rating on the shares. The Biotech sector enters 2026 on a cautiously optimistic note, the analyst tells investors in a research note. While capital absorption from secondary offerings is a concern, over $47B of pending capital from potential M&A could offset this, though sustained outperformance will likely require M&A activity to continue outpacing secondaries and IPOs, the firm says.

Citi

Buy

upgrade

$33 -> $36

2026-01-06

New

Reason

Citi

Price Target

$33 -> $36

2026-01-06

New

upgrade

Buy

Reason

Citi raised the firm's price target on Acadia Pharmaceuticals to $36 from $33 and keeps a Buy rating on the shares. The firm sees opportunities in SMID-cap biotech heading into 2026 for commercial or near-commercial stage companies. As part of its 2026 outlook, Citi upgraded both Arvinas and Krystal Biotech while adding an "upside 90-day catalyst watch" on Olema Oncology.

Needham

Buy

maintain

$29 -> $34

2026-01-05

New

Reason

Needham

Price Target

$29 -> $34

2026-01-05

New

maintain

Buy

Reason

Needham raised the firm's price target on Acadia Pharmaceuticals to $34 from $29 and keeps a Buy rating on the shares. The firm views the shares as undervalued despite the 50% increase in 2025. 2026 could be another strong year for Acadia with continued commercial execution and "de-risked upside" from the Phase 2 study data expected in mid-2026, the analyst tells investors in a research note.

Morgan Stanley

Michael Cyprys

Equal Weight

maintain

$46 -> $49

2025-12-17

Reason

Morgan Stanley

Michael Cyprys

Price Target

$46 -> $49

2025-12-17

maintain

Equal Weight

Reason

Morgan Stanley analyst Michael Cyprys raised the firm's price target on Acadian Asset Management to $49 from $46 and keeps an Equal Weight rating on the shares. Flows were softer than expected in Q4 and the firm is lowering its Q4 flow estimate by 30 basis points while cutting Q4 EPS estimates by 5% on average for the Asset Managers it covers, the analyst tells investors in a preview.

H.C. Wainwright

Buy

maintain

$32 -> $37

2025-12-15

Reason

H.C. Wainwright

Price Target

$32 -> $37

2025-12-15

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Acadia Pharmaceuticals to $37 from $32 and keeps a Buy rating on the shares following the approval of Daybue Stix. The approval unlocks access for patients who previously couldn't swallow the large liquid volumes, the analyst tells investors in a research note. The firm's key opinion leader analysis suggests the powder formulation could reduce stomach issues by removing specific additives, while solving the taste struggles that cause families to stop treatment.

Stifel

Paul Matteis

Hold

maintain

$24 -> $25

2025-12-11

Reason

Stifel

Paul Matteis

Price Target

$24 -> $25

2025-12-11

maintain

Hold

Reason

Stifel analyst Paul Matteis raised the firm's price target on Acadia Pharmaceuticals to $25 from $24 and keeps a Hold rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.

Valuation Metrics

The current forward P/E ratio for ACADIA Pharmaceuticals Inc (ACAD.O) is 39.74, compared to its 5-year average forward P/E of -6.67. For a more detailed relative valuation and DCF analysis to assess ACADIA Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.67

Current PE

39.74

Overvalued PE

75.69

Undervalued PE

-89.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

69.93

Current EV/EBITDA

41.38

Overvalued EV/EBITDA

378.63

Undervalued EV/EBITDA

-238.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.86

Current PS

3.69

Overvalued PS

7.44

Undervalued PS

2.29

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 713.31% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 713.31% over the last month.

Sold

Bought

ACAD News & Events

Events Timeline

No data

News

1.0

2025-12-18Newsfilter

Acadia Pharmaceuticals to Present at 2026 J.P. Morgan Healthcare Conference

5.0

2025-12-12Newsfilter

Acadia Receives FDA Approval for DAYBUE STIX Treatment of Rett Syndrome

9.0

2025-12-12NASDAQ.COM

FDA Grants Approval for Acadia's Powder Formulation of DAYBUE to Treat Rett Syndrome

People Also Watch

Frequently Asked Questions

What is ACADIA Pharmaceuticals Inc (ACAD) stock price today?

The current price of ACAD is 26.78 USD — it has decreased -0.48 % in the last trading day.

What is ACADIA Pharmaceuticals Inc (ACAD)'s business?

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

What is the price predicton of ACAD Stock?

What is ACADIA Pharmaceuticals Inc (ACAD)'s revenue for the last quarter?

ACADIA Pharmaceuticals Inc revenue for the last quarter amounts to 278.63M USD, increased 11.27 % YoY.

What is ACADIA Pharmaceuticals Inc (ACAD)'s earnings per share (EPS) for the last quarter?

ACADIA Pharmaceuticals Inc. EPS for the last quarter amounts to 0.42 USD, increased 110.00 % YoY.

What changes have occurred in the market's expectations for ACADIA Pharmaceuticals Inc (ACAD)'s fundamentals?

How many employees does ACADIA Pharmaceuticals Inc (ACAD). have?

ACADIA Pharmaceuticals Inc (ACAD) has 653 emplpoyees as of January 10 2026.

What is ACADIA Pharmaceuticals Inc (ACAD) market cap?

Today ACAD has the market capitalization of 4.53B USD.